PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19477216-5	2009	By contrast, ERW or silymarin supplement significantly ameliorated the CCl(4)-induced liver lesions, lowered the serum levels of hepatic enzyme markers (ALT and AST) and increased the activities of SOD, catalase, and GSH-Px in liver.	Silymarin	20-29	catalase	Mus musculus	203-211	
33976540-7	2021	Silymarin treatment also increased the SOD, CAT, GSH, GSH-Px, T-AOC, IL-10, and IL-12 levels, as well as reduced the MDA, NO, IL-6, IL-1beta, TNF-alpha, IFN-gamma levels in the mouse serum and liver tissues.	Silymarin	0-9	catalase	Mus musculus	44-47	
25026360-10	2014	Catalase (CAT) was increased due to high dose of silymarin (65.7 micromol/min/ml protein) compare with bleomycin treated-mice.	Silymarin	49-58	catalase	Mus musculus	0-8	
25026360-10	2014	Catalase (CAT) was increased due to high dose of silymarin (65.7 micromol/min/ml protein) compare with bleomycin treated-mice.	Silymarin	49-58	catalase	Mus musculus	10-13	
10753220-6	2000	The observed effects of silymarin were 18-66, 32-72 and 20-67% protection against BPO-induced depletion of SOD, catalase and GPX activity in mouse epidermis, respectively.	Silymarin	24-33	catalase	Mus musculus	112-120	
26758315-7	2016	Silymarin treatment reduced HFD-increased oxidative stress indicators (reactive oxygen species, lipid peroxidation, protein oxidation) and restored HFD-down-regulated activities of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase) in the plasma and/or liver of the HFD-fed mice.	Silymarin	0-9	catalase	Mus musculus	224-232	
10569809-6	1999	Similarly, these doses of silymarin also showed 39-90%, 29-85%, and 15-67% protection (P < 0.05 or 0.001), against TPA-caused depletion of epidermal superoxide dismutase, catalase, and glutathione peroxidase activity, respectively.	Silymarin	26-35	catalase	Mus musculus	174-182